CorMedix Acquires Heron's Hospital Portfolio, Adding Four Products for $145M Cash Plus Stock

What happened

CorMedix announced an agreement to acquire substantially all assets of Heron Therapeutics, gaining four commercial-stage hospital products—ZYNRELEF, APONVIE, CINVANTI, and SUSTOL—for $145 million in cash, 14,583,333 shares of CorMedix common stock, and up to $55 million in earn-outs tied to 2028 ZYNRELEF sales plus royalties on certain products. The transaction expands CorMedix's hospital and acute-care commercial platform, complementing its existing DefenCath in dialysis and the Melinta anti-infective portfolio acquired in 2025. Management expects the deal to be immediately accretive to earnings and free cash flow, with $45–60 million in near-term operating cost synergies. CorMedix will draw $75 million from a new senior secured term loan with Pharmakon Advisors to help fund the cash portion, while Heron will remain public with its credit facility repaid, a significant equity stake in CorMedix, and rights to earn-out and royalty payments. The transaction is expected to close in the first quarter of 2027, subject to regulatory clearance and approval by Heron stockholders.

Implication

The acquisition reduces CorMedix's reliance on DefenCath by adding four established hospital products, which could stabilize revenue as the dialysis drug faces a known reimbursement step-down in July 2026. However, the deal introduces significant execution risk: CorMedix must integrate a third commercial franchise (after Melinta) while managing a larger debt load and 18.5% share dilution. The claimed immediate accretion and $45–60 million synergies are management projections that may prove optimistic, especially given Heron's historical losses and the competitive hospital market for these products. The near-term catalyst remains DefenCath's utilization KPIs and Q2 2026 REZZAYO data, but the Heron deal shifts the narrative toward a broader hospital platform story that could re-rate the stock if integration succeeds. Until the deal closes and synergies materialize, caution is warranted, and the stock may trade with a higher risk premium.

Thesis delta

The prior thesis centered on DefenCath's utilization ramp before the July 2026 TDAPA reimbursement reset and Melinta as a diversification buffer. This acquisition materially accelerates diversification by adding four hospital products, reducing the single-asset risk that dominated the bear case. However, it also adds integration complexity, $75 million in new debt, and meaningful equity dilution, which raises the execution bar for management to achieve the promised accretion and synergies. The thesis shifts from a dialysis-focused reimbursement timing story to a multi-product hospital platform buildout, but the core risk now becomes CorMedix's ability to integrate three separate commercial organizations without losing focus on DefenCath's critical near-term revenue.